Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 262,297,072
  • Shares Outstanding, K 6,848,488
  • Annual Sales, $ 60,830 M
  • Annual Income, $ 10,735 M
  • 60-Month Beta 0.50
  • Price/Sales 4.48
  • Price/Cash Flow 13.25
  • Price/Book 8.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 07/25/19
  • Annual Dividend & Yield 0.68 (1.81%)
  • Most Recent Dividend 0.678 on 03/07/19
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.2200 +5.45%
on 10/22/19
38.3200 -0.33%
on 11/19/19
+1.3845 (+3.76%)
since 10/18/19
3-Month
33.7600 +13.14%
on 09/10/19
38.3200 -0.33%
on 11/19/19
+3.4845 (+10.04%)
since 08/20/19
52-Week
29.4500 +29.69%
on 12/27/18
38.3200 -0.33%
on 11/19/19
+7.2445 (+23.41%)
since 11/20/18

Most Recent Stories

More News
Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.

ABBV : 87.51 (-1.70%)
RHHBY : 38.2100 (-0.23%)
PFE : 37.21 (-1.19%)
AMGN : 224.51 (unch)
Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion

Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.

RHHBY : 38.2100 (-0.23%)
CELG : 107.87 (-0.24%)
ALKS : 20.27 (+1.60%)
ANIK : 59.93 (-0.33%)
Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs

Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.

AZN : 47.15 (-1.09%)
GSK : 43.92 (-1.30%)
RHHBY : 38.2100 (-0.23%)
IMGN : 3.40 (-2.30%)
Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

LEXINGTON, Mass. , Nov. 15, 2019 /PRNewswire/ -- Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior....

ROG : 130.42 (+1.05%)
RHHBY : 38.2100 (-0.23%)
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3

Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.

JNJ : 135.33 (+0.38%)
RHHBY : 38.2100 (-0.23%)
HALO : 19.35 (+1.04%)
TAK : 20.73 (-0.48%)
Roche's SMA Drug Meets Primary Endpoint in Pivotal Study

Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.

NVS : 90.59 (+0.21%)
RHHBY : 38.2100 (-0.23%)
BIIB : 287.63 (+0.77%)
PTCT : 44.30 (-1.29%)
Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review

Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.

MRK : 84.79 (+0.17%)
BMY : 55.79 (-1.22%)
BAYRY : 19.1100 (-1.60%)
RHHBY : 38.2100 (-0.23%)
AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL

AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.

ABBV : 87.51 (-1.70%)
RHHBY : 38.2100 (-0.23%)
JNJ : 135.33 (+0.38%)
BIIB : 287.63 (+0.77%)
Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus

Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.

RHHBY : 38.2100 (-0.23%)
GBT : 56.43 (+2.14%)
ALKS : 20.27 (+1.60%)
AVEO : 0.64 (+1.59%)
Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down

Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.

RHHBY : 38.2100 (-0.23%)
NVS : 90.59 (+0.21%)
PBYI : 8.58 (+2.14%)
VRTX : 215.28 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 38.4533
1st Resistance Point 38.3767
Last Price 38.2100
1st Support Level 38.1667
2nd Support Level 38.0333

See More

52-Week High 38.3200
Last Price 38.2100
Fibonacci 61.8% 34.9317
Fibonacci 50% 33.8850
Fibonacci 38.2% 32.8383
52-Week Low 29.4500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar